

Real World Experience of Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent *Clostridioides difficile*



Harris College of Nursing and Health Services
Texas Christian University

Kathy A. Baker Ph.D., APRN¹; Timothy E. Ritter, MD²; Jonathan A. Rosenberg, MD³; Richard L. Hengel MD⁴; Sujatha Krishan, MD⁵
Lucinda J. Van Anglen, BS, PharmD⁶; Kelly E. Hanna, PharmD⁶; Amy Guo, PhD⁷; Mielad Moosapanah, PharmD⁷; Kevin W. Garey, PharmD⁸

¹Harris College of Nursing and Health Sciences, Texas Christian University; ²GI Alliance, Southlake, TX; ³GI Alliance, Highland Park, IL; ⁴Atlanta ID Group, Atlanta, GA;

⁵DFW Infectious Disease, Dallas, TX; ⁶Healix Infusion Therapy, Sugar Land, TX; ⁷Ferring Pharmaceuticals; ⁸University of Houston College of Pharmacy, Houston, TX

Introduction

Clostridioides difficile infection (CDI) is a global healthcare concern, causing between 15,000–30,000 deaths and healthcare costs exceeding \$4.8 billion annually [1]. Even with appropriate treatment of CDI with standard-of-care (SoC) antibiotic therapy, first recurrences continue in up to 35% of patients following an initial episode [2-5]. While treating the CDI, SoC antibiotics disrupt the gut microbiota, increasing the risk for further recurrent CDI (rCDI). Microbial restoration with live biotherapeutic products may restore the diversity and composition of the gut microbiota to decrease the likelihood of rCDI.

Fecal Microbiota, live-jslm (RBL) is a rectally administered, pre-packaged, live biotherapeutic approved in November 2022 for the prevention of recurrence of *Clostridioides difficile* infection (rCDI) in adults [6]. Clinical trial data indicates success in prevention of recurrence [7,8] for RBL, the first FDA-approved microbiota product. Study is warranted of whether RBL, a novel therapy in preventing rCDI, may pose challenges in routine clinical administration, particularly with Gastroenterology (GI) and Infectious Disease (ID) practices or other specialties not commonly providing rectally administered therapies.

Objectives

The objective of this study is to develop and report implementation of a simple administration protocol of RBL for rCDI prevention in routine clinical practice.

Methods

Study Design: Retrospective, multicenter cohort study conducted in physician office infusion centers (POICs) in the United States.

Patient Population: All patients who received at least one dose of RBL from February 2023 through August 2023.

Protocol: A multi-disciplinary protocol was developed for provision of RBL through POICs. Development included the following:

- Protocol designed by Nursing, Pharmacy, Business Office (BO), Operations, and Purchasing
- Certificate of Medical Necessity (CMN) for insurance approval
- Order set
- Guidelines for use:
 - Referral and order management
 - Notification to BO and Clinical Team of a new urgent (STAT) order
 - Insurance approval and submission of co-pay assistance, if applicable
 - Scheduling of patient with coordination of antibiotic discontinuation
 - Acquisition of RBL
 - Pre-appointment confirmation
 - Appointment procedures with preparation and administration

Data collection: Electronic medical records (EMR), administration records and internal databases were queried, and the following data collected:

- Patient demographics, including payer detail
- History of present illness (HPI) for current and past episodes of CDI
- CDI stool test results and antimicrobial therapy
- Time from order to treatment
- Nursing assessment for RBL administration
- Adverse effects during the procedure

Data Analysis: Continuous and categorical variables were reported using mean ± standard deviation (SD) or median with interquartile range (IQR) and frequency (percentage), respectively.

Study Cohort

Table 1. Patient Characteristics

- 25 patients from 12 POICs in 8 states received RBL through 8/31/2023.
- Patients received treatment in GI POICs (n=14) and in ID POICs (n=11).

Characteristic	Results (N=25)
Age, years (mean±SD)	69±17
Age ≥65 years	17 (68%)
Female	17 (68%)
CDI episodes, including current, median (IQR)	4 (3-4)
SoC Antibiotic for the current episode of CDI	
Vancomycin	12 (48%)
Fidaxomicin	8 (32%)
Fidaxomicin and vancomycin	4 (16%)
Other*	2 (8%)
Health Insurance	
Commercial	9 (36%)
Medicare, Traditional	9 (36%)
Medicare Advantage Plan	7 (28%)

*vancomycin + metronidazole (n=1), unknown antibiotic (n=1). Data are presented as no. (%) unless otherwise indicated.

Figure 1. Certificate of Medical Necessity

Certificate of Medical Necessity
Fecal Microbiota (Rebyota) for the Prevention of Recurrence of *Clostridioides difficile* Infection (CDI)

Patient Name: _____ Site: _____

1. Diagnosis:
 A04.71 Enterocolitis due to *Clostridium difficile*, recurrent

2. Has the patient received this treatment at another facility? Yes No
 If YES, a. Last Treatment Date: _____ b. Facility Name: _____

3. Is the patient 18 years of age or older? Yes No

4. HPI indicates clear evidence of recurrent CDI diagnosis? Yes No
 If YES, a. Number of previous CDI episodes: _____

5. Was the patient born completed at a source of antibiotic therapy for the most recent CDI episode? Yes No
 If YES, a. Date(s) of previous CDI episode(s): _____
 b. Antibiotic therapy for CDI: _____
 c. Date Started: _____
 d. Anticipated Stop Date: _____

6. Is the patient's current CDI episode well controlled (i.e., reduced stool frequency)? Yes No

7. Was CDI confirmed with positive stool testing? Yes No
 Date stool sample collected: _____
 Stool test for *C. difficile* toxin A and B Toxinigenic stool culture for *C. difficile* toxin
 Cell cytotoxic assay for *C. difficile* toxin PCR assay for *C. difficile* toxin
 Other: _____

8. Other information:

From Completed by: _____ Date: _____

Rebyota™ is medically necessary for the prevention of recurrence of *Clostridioides difficile* infection (CDI) in this adult patient following antibiotic treatment for recurrent CDI.


Physician Signature: _____ Date: _____

Table 2. Treatment Criteria

RBL Protocol Treatment Criteria
Primary Diagnosis: Enterocolitis due to <i>Clostridium difficile</i> , recurrent (ICD-10 Code: A04.71)
Patient Age (required to be ≥18 years)
Completion of Certificate of Medical Necessity, including the following:
History and Physical Clear indication of current episode of recurrent CDI No. of prior CDI episodes and dates
Positive stool test(s) for current episode, with type of test and dates
Antibiotic therapy for the current CDI episode Antibiotic regimen and planned stop date (to plan for RBL administration)
Confirmation of control of symptoms with the current episode

Logistical Flow

Figure 2. Process Flow



*RBL is ordered 2-4 days ahead of a confirmed appointment to allow for drug delivery and thawing. RBL must be thawed under refrigeration for 24 hours prior to use and may be stored for up to 5 days.


Table 3. Clinical and Administration Protocol

RBL Clinical Protocol
Appointment Coordination Ensure the SoC antibiotic has been discontinued at least 24-72 hours prior to RBL administration. Order RBL 2-4 days prior to the appointment for overnight delivery Tuesday through Friday. Store RBL in the refrigerator immediately upon receipt. (Outside of a -70°C environment, RBL is stable for 5 days refrigerated.)
Pre-appointment Confirmation (24 hours prior) Confirm patient does not have active diarrhea or continuing CDI symptoms. Confirm the SoC antibiotic has been or will be discontinued at least 24-72 hours before the appointment. Thaw RBL in the refrigerator for 24 hours prior to the appointment. Request patient to empty bladder or bowel prior the appointment, but not to perform any bowel prep.
RBL Administration Greet patient and room them in a private room with an exam table. Have patient empty bladder and bowels if not done prior to appointment. Don proper PPE and follow infection control guidelines for <i>Clostridioides difficile</i> . Retrieve RBL from the refrigerator just prior to administration. Place underpad on the exam table and position patient in a position as noted in Figure 3. Prepare RBL for administration with attachment of provided tubing and apply lubricant to tip. Administer single dose of RBL 150 mL immediately via gravity flow over 5 minutes. Keep patient in the same position and observe for 15 minutes to minimize cramping. Discharge patient from the clinic (may use bathroom prior to leaving if needed).

Abbreviations: PPE, personal protective equipment

Administration

Figure 3. Administration Diagrams



Left-side position: Lie on left side with knee bent and arms resting comfortably.

Knee-chest position: Kneel, then lower head and chest forward until left side of face is resting on surface with left arm folded comfortably.

Figure 4. RBL Order

Fecal Microbiota, Live-jslm (Rebyota) Order

Practice Name: _____
 CHS, Inc.
 10000 N. Loop West, Suite 1000, Houston, TX 77040

Patient Name: _____ Date: _____
 CHS ID: _____ HPI: _____ ICD-10 Code: _____
 Diagnosis: _____
 Order: _____

Rebyota Order:
 Rebyota (live-jslm) 150 mL, gravity flow over 5 minutes.
 • Add to a previously ordered SoC antibiotic regimen.
 • Administer single dose of Rebyota 150 mL immediately via gravity flow over 5 minutes.
 • Keep patient in the same position and observe for 15 minutes to minimize cramping.
 • Discharge patient from the clinic (may use bathroom prior to leaving if needed).

Monitoring Parameters:
 • Monitor patient for signs and symptoms of an acute hypersensitivity reaction and seek immediate medical attention if a reaction occurs.
 • Monitor patient for signs and symptoms of an acute hypersensitivity reaction and seek immediate medical attention if a reaction occurs.
 • Monitor patient for signs and symptoms of an acute hypersensitivity reaction and seek immediate medical attention if a reaction occurs.

Additional Orders:
 • Discharge patient from the clinic (may use bathroom prior to leaving if needed).
 • Discharge patient from the clinic (may use bathroom prior to leaving if needed).
 • Discharge patient from the clinic (may use bathroom prior to leaving if needed).

Ordering Physician Name: _____ Physician Signature: _____ Date: _____
 V.D. Name: _____ Physician: _____ Clinician Signature: _____ Date: _____

Table 4. Administration Outcomes

Parameter	Cohort	
	No. of pts (N=25)*	Result
Time from order to RBL administration, median days (IQR)	25	19 (17-30)
Insillation time via gravity flow, minutes, median (IQR)	12	6 (5-12)
Observation time, minutes	17	15
Administration position	16	-
Left lateral	-	15
Right lateral	-	1
Knee-Chest	-	0
Healthcare provider administering	22	-
Registered Nurse	-	16
Licensed Vocational Nurse	-	3
Nurse Practitioner	-	2
Physician	-	1
Adverse effects reported during the procedure	22	0
Reports of rectal leakage	22	0
Patients with bowel movement after the procedure	22	4

*Numbers noted for each parameter reflect those reported.

Discussion

This multicenter study involved the development of a simple protocol for administration of RBL, with subsequent analysis of the protocol. RBL is a rectally administered, pre-packaged, live biotherapeutic for the prevention of rCDI in adults.

- 25 patients received RBL following development and initiation of a protocol for use in 12 physician office infusion centers.
- Patients were older (69±17 years), majority female (68%) and most (64%) Medicare (Traditional or Medicare Advantage) recipients. Patients had a median of 4 episodes of CDI, including the current episode. Vancomycin was the most used SoC antibiotic for treatment of CDI.
- Protocol key success factors were:
 - Rapid compilation of required records for insurance approval following identification of rCDI. Median approval was 19 days from order to treatment.
 - Training for the nurses of the protocol and procedures for management, drug ordering, patient communication, and administration
 - Prompt order placement and receipt of RBL to meet appointments.
- The nurses confirmed completion of SoC at least 24-72 hours prior to administration of RBL.
- Administration of RBL was performed most often by registered nurses.
- RBL was instilled mostly in the left lateral position and completed in 6 minutes with 15 minutes of observation. No leakage or adverse events occurred.
- All patients adhered to appointments and received RBL as planned.

Conclusion

- **Development of a standardized protocol was critical in facilitation of RBL therapy in physician office infusion centers, particularly for nurses not familiar with rectal administration.**
- **Overall patient visit time and administration of RBL was brief and safe.**
- **RBL holds promise as a simple office-based therapy for the prevention of rCDI.**

References

1. McDonald LC, et al. Clin Infect Dis. 2018; 66:e1-e48.
2. Johnson S, et al. Clin Infect Dis. 2021;73(5):e1029-44.
3. Guh A, et al. N Engl J Med. 2020; 382:1320-1330
4. Cornely OA, et al. Clin Infect Dis. 2012; 55:S154-61.
5. Ma GK, et al. Ann Intern Med. 2017; 167:152-8.
6. Rebyota (fecal microbiota, live - jslm) [package insert]. Roseville, MN: Ferring Pharmaceuticals; 2022.
7. Dubberke ER, et al. Infect Dis Ther. 2023; 12:703–710.
8. Khanna S, et al. Drugs. 2022; 82:1527–1538.